Claire Mulvey, MD
Hematology & Oncology · San Francisco, CANPI 1962845198
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,935 of the $6,499 with a category attached, or 75.9%. 4 manufacturers reported payments, led by Genentech USA, Inc. at 37.7% of the total.
Across 6 payments — averaging $1083.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$2K
- Pfizer$1K
- Johnson & Johnson$1K
- Jazz Pharmaceuticals Inc.$1K
Across 27 payments — averaging $15,666 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$198K
- Amgen$183K
- Daiichi Sankyo Inc.$42K
What the payments were for
- Consulting fees$4,93576%
- Speaking & faculty fees$1,44022%
- Food & beverage$1242%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 3 | $2,449 |
| Pfizer | 1 | $1,440 |
| Johnson & Johnson | 1 | $1,350 |
| Jazz Pharmaceuticals Inc. | 1 | $1,260 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,499 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 58 | $916,311 |
| Ondansetron Hcl | 39 | $570 |
| Prochlorperazine Maleate | 36 | $451 |
| Dexamethasone | 27 | $329 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in San Francisco
- Pamela KleinSan Francisco$510K
- Aaron LoganSan Francisco$333K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.